GRI Bio (GRI) Gains from Investment Securities (2022 - 2024)
GRI Bio (GRI) posted quarterly Gains from Investment Securities of -$1000.0 for Q2 2024, down 101.59% year-over-year from $63000.0 in Q3 2023, and up 50.0% quarter-over-quarter from -$2000.0 in Q1 2024.
GRI Bio (GRI) Gains from Investment Securities (2022 - 2024) Analysis & Trends
GRI Bio's Gains from Investment Securities history runs 3 years deep, the most recent figure standing at -$1000.0 for Q2 2024.
- In Q2 2024, Gains from Investment Securities fell 101.59% year-over-year to -$1000.0; the TTM figure through Mar 2025 stood at -$1000.0 (up 99.46% YoY), while the FY2024 annual figure was -$3000.0, up 98.35% from the prior year.
- Gains from Investment Securities for Q2 2024 stood at -$1000.0, up from -$2000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $266000.0 in Q2 2022, with the low at -$757000.0 in Q3 2022.
- The 3-year median for Gains from Investment Securities is -$2000.0 (2024), against an average of -$96571.4.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities soared 94.06% in 2023, then plunged 101.59% in 2024.
- GRI Bio's Gains from Investment Securities stood at -$757000.0 in 2022, then jumped by 73.58% to -$200000.0 in 2023, then jumped by 99.5% to -$1000.0 in 2024.
- Business Quant data shows GRI's Gains from Investment Securities at -$1000.0 in Q2 2024, -$2000.0 in Q1 2024, and -$200000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | -200,000.00 |
| Dec 31, 2023 | -200,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Jun 30, 2023 | 63,000.00 |
| Jun 30, 2023 | 63,000.00 |
| Sep 30, 2022 | -757,000.00 |
| Sep 30, 2022 | -757,000.00 |
| Jun 30, 2022 | 266,000.00 |
| Jun 30, 2022 | 266,000.00 |